Search Tufts Medicine

This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

The total duration of this study for each participant is approximately 28 weeks, which includes a screening period of 4 weeks, followed by a 24-week double blind placebo-controlled treatment period. At the end of the treatment period, all participants will have the option to enter a separate study, the blinded extension study

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, symptomatic AS. The primary objective is to demonstrate the safety and effectiveness of the Medtronic TAVR system (on the background of GDMT) is superior to GDMT alone.

Study CTQJ230A12203 is a phase 2 clinical trial which aims to evaluate if treatment with pelacarsen (TQJ230) versus placebo slows the progression of mild or moderate calcific aortic valve stenosis, and to further characterize the safety profile of the drug.